Glycomark announced a study at the American Diabetes Association Scientific Sessions 2019. Aveon Health participated in the study from 2015 to 2018 in which 92% of patients treated with an SGLT-2 inhibitor reported a Glycomark result averaging 1.2µg/mL. These extremely low Gycomark results are not an indicator of poor glycemic control but rather an indication of medication adherence, achieving the desired effect by eliminating glucose in the urine.
The Glycomark test has been used by clinicians of Aveon Health for the past 8 years. Upon founding Aveon Health in 2014 our clinicians kept using these tests to understand and control our patient’s glucose levels.
Read the full article here